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Abstract Increased activation of the PI3K/Akt/mTOR
pathway is a common factor in putative mechanisms of
trastuzumab resistance, resulting in dysregulation of cell
migration, growth, proliferation, and survival. Data from
preclinical and phase 1/2 clinical studies suggest that adding
everolimus (an oral mTOR inhibitor) to trastuzumab plus
chemotherapy may enhance the efficacy of, and restore
sensitivity to, trastuzumab-based therapy. In this phase 2
multicenter study, adult patients with HER2-positive
advanced breast cancer resistant to trastuzumab and pretreated
with a taxane received everolimus 10 mg/day in combination
with paclitaxel (80 mg/m2 days 1, 8, and 15 every 4 weeks)
and trastuzumab (4 mg/kg loading dose followed by 2 mg/kg
weekly), administered in 28-day cycles. Endpoints included
overall response rate (ORR), progression-free survival (PFS),
overall survival (OS), and safety. Fifty-five patients were
enrolled; one remained on study treatment at the time of dataPresented at 2010 ASCO annual meeting; abstract published as
Dalenc F, et al. J Clin Oncol. 2010; 28(May 20 suppl), Abstract 1013.
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cutoff. The median number of prior chemotherapy lines for
advanced disease was 3.5 (range 1–11). The ORR was 21.8 %,
the clinical benefit rate was 36.4 %, the median PFS estimate
was 5.5 months (95 % confidence interval [CI]:
4.99–7.69 months), and the median OS estimate was
18.1 months (95 % CI: 12.85–24.11 months). Hematologic
grade 3/4 adverse events (AEs) included neutropenia (25.5 %
grade 3, 3.6 % grade 4), anemia (7.3 % grade 3), and
thrombocytopenia (5.5 % grade 3, 1.8 % grade 4). Nonhe-
matologic grade 3/4 AEs included stomatitis (20.0 %), diar-
rhea (5.5 %), vomiting (5.5 %), fatigue (5.5 %), and
pneumonia (5.5 %), all grade 3. These findings suggest that
the combination of everolimus plus trastuzumab and paclit-
axel is feasible, with promising activity in patients with highly
resistant HER2-positive advanced breast cancer. This com-
bination is currently under investigation in the BOLERO-1
phase 3 trial.
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TRAS Trastuzumab
WHO World Health Organization
Introduction
Overexpression of the tyrosine kinase human epidermal
growth factor receptor-2 (HER2) due to amplification of
the HER2/neu proto-oncogene is reported in nearly 25 %
of all breast cancers and is associated with aggressive
breast cancer cell growth [1, 2]. In clinical practice, HER2
protein overexpression or amplification is linked to poor
prognosis, increased risk of metastases, reduced disease-
free survival, and increased mortality [3, 4]. Agents that
target HER2, such as trastuzumab, pertuzumab, T-DM1,
and lapatinib, have been shown to improve clinical out-
comes in patients with HER2-positive breast cancer via
down-regulation or inhibition of HER2 activity [5–7].
Trastuzumab, which targets the extracellular domain of
HER2, has become the cornerstone of combination thera-
pies for HER2-positive early and advanced breast cancer
based on the results of numerous clinical trials [6, 8, 9].
Despite the success of these HER2-directed therapies, the
majority of patients with advanced breast cancer relapse or
progress [10]. Resistance to trastuzumab is a major clinical
concern with room for improvement, considering that the
response rates to initial trastuzumab treatment range between
33 and 50 % in patients with HER2-positive advanced breast
cancer [11, 12]. In addition, 70 % of patients with initial
response to trastuzumab treatment experience disease pro-
gression within 1 year [13]. Therefore, additional treatment
options are needed to effectively manage HER2-positive
advanced breast cancer. Trastuzumab resistance is hypoth-
esized to occur via a number of mechanisms, including
increased signaling mediated by upstream growth factor
receptors, alterations of the HER2 receptor, phosphatase and
tensin (PTEN) deficiency, and constitutive activation of
phosphatidylinositol 3-kinase (PI3K) [3, 5, 13].
Increased activation of the PI3K/protein kinase B (Akt)/
mammalian target of rapamycin (mTOR) pathway results
in dysregulation of cell migration, growth, proliferation,
and survival [14]. Therefore, agents that inhibit the PI3K/
Akt/mTOR pathway may restore sensitivity to trast-
uzumab-based therapy. This hypothesis is supported by
preclinical studies in which PI3K inhibitors overcame
PTEN loss-induced trastuzumab resistance and slowed the
growth of HER2-positive breast cancer cells in vitro and
in vivo [15, 16].
Everolimus is an oral mTOR inhibitor approved for sev-
eral oncology indications, including the treatment of patients
with hormone-receptor-positive advanced breast cancer
recurring or progressing during or after treatment with
nonsteroidal aromatase inhibitors [17, 18]. A phase 1b/2
study was conducted in patients with taxane-pretreated and
trastuzumab-resistant HER2-positive advanced breast can-
cer to determine the optimal dose and schedule of everolimus
in combination with weekly trastuzumab and paclitaxel. The
phase 1b portion of the study reported encouraging antitumor
activity and generally good tolerability when everolimus
(5 mg/day, 10 mg/day, or 30 mg/week) was combined with
weekly trastuzumab and paclitaxel [19]. The overall
response rate (ORR) was 44 %, and median progression-free
survival (PFS) was approximately 8 months. The current
report from the phase 2 portion of this study provides further
insights into the efficacy and safety of daily everolimus
(10 mg) in combination with weekly paclitaxel and trast-
uzumab in patients with trastuzumab-resistant HER2-posi-
tive advanced breast cancer.
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Patients and methods
Study design and patients
J2101 was an open-label, multicenter, phase 2 study with a
Simon 2-stage design, involving patients with HER2-
positive advanced breast cancer whose disease progressed
on or after trastuzumab and taxane therapy. The Simon
2-stage design was considered optimal to allow for early
termination of the study after stage 1 in case of lack of
efficacy. In the first stage, 30 patients were to be enrolled.
If two or more patients achieved a response in the first
stage, an additional 22 patients were to be enrolled;
otherwise, the study was to be stopped.
Adult patients (C18 years of age) with histologically
confirmed HER2-positive advanced breast cancer (immu-
nohistochemistry 3? or positive fluorescence in situ
hybridization) whose disease progressed during or within
3 months of receiving the last dose of trastuzumab for
advanced disease or recurred within 12 months of com-
pleting trastuzumab-based (neo)adjuvant therapy were eli-
gible to enroll. In addition, patients were required to have
experienced disease progression during or within 6 months
of the last taxane dose (with or without documented
response) for advanced disease, or recurrence within
12 months of completing taxane-based chemotherapy as
(neo)adjuvant therapy. Other eligibility criteria included a
World Health Organization (WHO) performance status of 0
or 1, measurable disease according to response evaluation
criteria in solid tumors (RECIST) 1.0, left ventricular
ejection fraction greater than 50 %, and adequate bone
marrow, liver, and renal function. Exclusion criteria
included uncontrolled or symptomatic central nervous
system metastases; prior chemotherapy, immunotherapy, or
radiotherapy within 4 weeks or prior lapatinib within
2 weeks of study entry; prior treatment with endocrine
therapy for breast cancer (endocrine therapy had to have
either failed in patients with hormone-receptor-positive
disease within 2 weeks of randomization or patients had to
be deemed unsuitable for endocrine therapy); or previous
exposure to mTOR inhibitors.
All patients provided written informed consent before
registration. The J2101 study was conducted in accordance
with the Declaration of Helsinki and with local ethics
committee approval at each participating center (16 centers
in Belgium, France, The Netherlands, Spain, and the Uni-
ted States).
Treatment
For the current single-arm phase 2 study, enrolled patients
received daily oral everolimus 10 mg plus weekly trast-
uzumab and paclitaxel administered in 28-day cycles. The
10 mg/day dose of everolimus used was determined based
on the efficacy and safety findings in the 3-arm phase 1b
dose-escalation portion of this study, in which two daily
regimens (5 and 10 mg/day) and 1 weekly regimen
(30 mg/week) were examined [19]. Among these, everol-
imus 10 mg/day was chosen for further development on the
basis of observed dose-limiting toxicity (grade 1/2 stoma-
titis at the end of cycle 1) and overall safety.
In addition to daily everolimus, all patients in this phase
2 study received weekly trastuzumab and paclitaxel infu-
sion (80 mg/m2 on days 1, 8, and 15 of each cycle for at
least six cycles). Trastuzumab was administered intrave-
nously at a loading dose of 4 mg/kg on day 1 of cycle 1,
with a maintenance dose of 2 mg/kg thereafter. Following
completion of the first six cycles, patients continued to
receive everolimus and trastuzumab, while continuation of
paclitaxel was allowed at the investigator’s discretion. For
those patients who did not continue paclitaxel beyond the
first six cycles, trastuzumab was administered once every
3 weeks at a dose of 6 mg/kg. Patients could receive ev-
erolimus alone (if trastuzumab was discontinued early
because of toxicity) or with trastuzumab until disease
progression or unacceptable toxicity occurred.
In addition to the study treatments, prophylactic use of
antiemetics was recommended. Patients were allowed to
continue baseline bisphosphonate or analgesic therapy. In
the event of documented cytopenia (after the first cycle of
treatment), the use of hematopoietic growth factors was
permitted.
Study objectives
The primary endpoint of the study was ORR as assessed by
RECIST 1.0. Secondary endpoints included PFS, overall
survival (OS), clinical benefit rate (CBR), and safety.
Study assessments
All baseline assessments were obtained at visit 1 (within
3 weeks before start of treatment). These evaluations
included physical and neurologic examinations, WHO
performance status, vital signs, height, weight, electrocar-
diogram, chest X-ray, cardiac imaging, pulmonary function
tests, demographics, medical history, confirmation of
HER2-positive metastatic breast cancer diagnosis, extent of
cancer, documentations of prior therapy, tumor assessment,
laboratory evaluations, and a pregnancy test.
Assessment of clinical response
Radiologic assessments (computed tomography [CT] scan,
magnetic resonance imaging) and/or physical examination
Breast Cancer Res Treat (2013) 141:437–446 439
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were performed every 8 weeks during the first six cycles of
study treatment. Patients continuing on everolimus and
trastuzumab beyond the first six cycles had radiologic
assessments performed every 9 weeks (every 8 weeks if
paclitaxel was continued) until disease progression or study
discontinuation for any other reason.
Assessment of safety
Adverse events (AEs) and laboratory assessments for
safety were evaluated throughout the study. AEs were
assessed according to National Cancer Institute/National
Institutes of Health Common Terminology Criteria for
AEs, version 3.0. Cardiac imaging (multigated angiogram
or echocardiogram) and electrocardiograms were repeated
every 12 weeks (or as clinically indicated). Chest X-rays
were performed every two cycles and, if clinically indi-
cated, chest CT scans were performed to monitor for
interstitial pneumonitis. Pulmonary function tests (spi-
rometry, carbon monoxide diffusing capacity [DLCO], and
room air oxygen saturation at rest) were performed at
baseline and on suspicion of noninfectious pneumonitis.
Everolimus dose interruptions and/or reductions were
allowed for specific AEs such as grade 2/3 pneumonitis,
grade C2 neurotoxicity, and grade C3 AEs (except hyper-
lipidemia and hyperglycemia) until the AE resolved to grade
B1. If necessary, the everolimus dose was reduced from 10 to
5 mg/day or from 5 to 2.5 mg/day. The dose of paclitaxel
could be reduced by 10 mg/m2 (for grade C2 pneumonitis or
other intolerable grade C2 AEs except neurotoxicity) or by
20 mg/m2 (for hematologic toxicities or grade C2 neuro-
toxicity) if dose interruption did not result in AE resolution to
grade B1. No dose reductions were allowed for trastuzumab;
however, dose interruption was permitted to control infu-
sion-related symptoms and for AEs such as a decrease in left
ventricular ejection fraction of C10 points from baseline or
\50 %, or development of grade C3 pneumonitis. Treat-
ment discontinuation was recommended for any toxicity
requiring interruption for more than 3 weeks and was
required for grade 4 pneumonitis.
Statistical analysis
The Simon 2-stage analysis was based on the intent-to-treat
population and was designed with 80 % power to reject the
null hypothesis when the true response rate is 15 %.
Overall response rates are presented with exact 2-sided
95 % confidence interval (CI), as determined via the
Clopper–Pearson method. PFS and OS were estimated
using the Kaplan–Meier method and are presented with the
2-sided 95 % CI.
Results
Patients
A total of 55 women were enrolled from February to
November 2009. The median age of patients enrolled was
56 years, and 83.6 % of the patients were under 65 years of
age. Sixty-six percent had a WHO performance status of 0
and 78 % had visceral disease. These patients were heavily
pretreated, with a median of 3.5 prior lines of chemother-
apy for metastatic disease. All patients had previously
received trastuzumab and taxane; 40 (73 %) and 35 (64 %)
patients had received prior anthracycline or lapatinib,
respectively. Resistance to trastuzumab was documented in
52 (95 %) patients; resistance to taxane or lapatinib was
reported in 40 (73 %) and 33 (60 %) patients, respectively
(Table 1).
Of the 55 patients enrolled in the study, 28 (50.9 %)
completed six cycles of treatment, and 24 of these patients
continued study treatment beyond six cycles (Table 2). At
the cutoff date (March 15, 2012), one patient was still
receiving study treatment. Among the 55 enrolled patients,
37 (67.3 %) discontinued treatment due to progressive
disease: 16 (29.1 %) patients during the first six cycles and
21 patients who continued treatment beyond the first six
cycles. A total of 10 patients discontinued study treatment
because of AEs; eight of these patients discontinued during
the first six cycles of study treatment. AEs resulting in
discontinuation from the study during the first six cycles
included ascites and general physical health deterioration
(n = 1); decreased performance status and fatigue (n = 1);
febrile neutropenia and sepsis (n = 1); decreased total lung
capacity and lung disorder (n = 1); and pneumonitis,
pneumonia, interstitial lung disease, and decreased DLCO
(n = 1 each). Two patients discontinued treatment because
of AEs after the first six cycles: brain edema (n = 1) and
decreased forced expiratory volume and dysphonia
(n = 1). Most of these AEs were suspected to be related to
study treatment.
The median duration of exposure to both everolimus and
trastuzumab was 24.0 weeks, whereas the median duration
of exposure to paclitaxel was 21.7 weeks (Table 3).
Patients were followed for a median of 32.6 months
(median treatment start date to data cutoff date). The
median dose intensity of everolimus was 8.75 mg/day;
median dose intensities of trastuzumab and paclitaxel were
0.29 and 7.09 mg/day, respectively (Table 3). The relative
dose intensities of everolimus, trastuzumab, and paclitaxel
were 0.88, 1.00, and 0.83, respectively. Overall, 47.3 and
89.1 % of patients required at least one dose reduction or
interruption of any study drug, respectively (Table 3). The
proportions of patients requiring at least one dose reduction
were 34.5 % for everolimus (30.9 % for AEs), 25.5 % for
440 Breast Cancer Res Treat (2013) 141:437–446
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paclitaxel (21.8 % for AEs), and none for trastuzumab per
protocol. At least one everolimus dose interruption was
required for 70.9 % of patients (61.8 % for AEs), 67.3 %
of patients required a paclitaxel dose interruption (65.5 %
for AEs), and 45.5 % of patients required a trastuzumab
dose interruption (34.5 % for AEs).
Clinical activity
The trial met its primary endpoint with 12 partial respon-
ses, resulting in an ORR of 21.8 % (Table 4). Disease
stabilization was achieved in 26 (47.3 %) patients, whereas
eight (14.5 %) patients had progressive disease. The dis-
ease control rate (defined as ORR plus stable disease) was
69.1 % and the CBR (defined as ORR plus stable disease
lasting 24 weeks or longer) was 36.4 %. Overall, at the
time of data cutoff, there were 36 PFS events (34 pro-
gressive disease and two deaths) based on local radiology
review, and the median PFS estimate was 5.5 months
(95 % CI: 4.99–7.69 months; Fig. 1). The median OS
estimate since start of the study was 18.1 months (95 % CI:
12.85–24.11 months; Fig. 2).
Tolerability
The incidences of AEs were consistent with the known
safety profiles of the study drugs (Table 5). All 55 patients
reported AEs while on study treatment. Of these, 48
patients (87.3 %) experienced grade 3/4 AEs, 26 patients
(47.3 %) had serious AEs, and 16 patients (29.1 %) had
AEs leading to discontinuation of at least one of the study
treatments. Three deaths occurred on treatment (during
study treatment or within 28 days of last treatment): two
Table 1 Demographic and baseline disease characteristics of patients
Everolimus ? trastuzumab ?
paclitaxel (N = 55)
Age, years
Median (range) 56.0 (31–83)
Age, n (%)
\65 years 46 (83.6)
C65 years 9 (16.4)
WHO performance status, n (%)
0 36 (65.5)
1 19 (34.5)
Predominant race, n (%)
Caucasian 48 (87.3)
Black 4 (7.3)
Asian 0
Native American 0
Pacific Islander 0
Other 3 (5.5)
Visceral disease, n (%)
Any 43 (78.2)
Lung 24 (43.6)
Liver 29 (52.7)
Target lesions, n (%)
Yes 52 (94.5)
No 3 (5.5)
Current stage of cancer, n (%)
IV 55 (100)
Disease-free interval, na 32
Median weeks (range) 108.9 (3–439)
Number of previous chemotherapy
lines for advanced disease
Median (range) 3.5 (1–11)
Pretreatment for advanced
disease, n (%)
Trastuzumab 55 (100.0)
Taxane 55 (100.0)
Lapatinib 35 (63.6)
Anthracycline 40 (72.7)
Resistance, n (%)
Trastuzumab 52 (94.5)
Taxane 40 (72.7)
Lapatinib 33 (60 0)
WHO World Health Organization
a Disease-free interval is calculated as the interval between date of
first surgery with no residual disease and date of first recurrence of
disease
Table 2 Patient disposition (full analysis set; N = 55)
Everolimus ? trastuzumab ?
paclitaxel, n (%)
First six cycles
Enrolled 55 (100)
Completed six cycles 28 (50.9)
Continued beyond six cyclesa 24 (43.6)
Discontinued 27 (49.1)
Disease progression 16 (29.1)
Adverse events(s) 8 (14.5)
Patient withdrew consent 3 (5.5)
Continued beyond six cyclesb 0
Beyond first six cycles
Continued beyond six cycles 24
Ongoing 1
Discontinued 23
Disease progression 21
Adverse event(s) 2
a Percentage of patients continuing beyond six cycles who completed
first six cycles
b Percentage of patients continuing beyond six cycles who discon-
tinued during first six cycles
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were attributable to disease progression and one to sepsis
(suspected by the investigator to be related to study drug).
The most common AEs were stomatitis (76.4 %), diarrhea
(56.4 %), asthenia (50.9 %), rash (47.3 %), headache
(43.6 %), and pyrexia (40.0 %). The most common grade
3/4 AEs (regardless of study treatment) reported in at least
5 % of patients were neutropenia, stomatitis, lymphopenia,
leukopenia, anemia, thrombocytopenia, diarrhea, vomiting,
fatigue, and pneumonia.
Most of the clinically notable AEs associated with ev-
erolimus were grade 1 or 2; among those that were grade 3
or 4, most were manageable by dose adjustments and/or
concomitant medications. Cytopenias were reported in 30
(54.5 %) patients and were suspected to be related to study
treatment; these were mostly managed by dose interruption
and/or dose reduction. Only one patient discontinued pac-
litaxel early due to thrombocytopenia. Stomatitis, the most
frequently reported nonhematologic, clinically notable AE,
was primarily grade 1/2 (56.4 %) and the remainder grade
3 (20 %). None of these patients discontinued study
Table 3 Treatment characteristics (safety population; N = 55)
Everolimus Trastuzumab Paclitaxel Any
Mean total dose, mg (SD) 1045.5 (541.56) 37.2 (13.96) 906.7 (415.78)
Median duration of exposure, weeks 24.00a 24.00a 21.71a 24.00b
Range 1.7–122.7 2.0–95.0 2.7–68.0 2.7–122.7
Mean dose intensity, mg/day (SD) 7.69 (2.243) 0.28 (0.027) 6.85 (1.536)
Median dose intensity, mg/day 8.75 0.29 7.09
Range 3.4–10.0 0.2–0.3 2.5–8.8
Median relative dose intensityc 0.875 1.003 0.827
Range 0.34–1.00 0.69–1.19 0.30–1.02
C1 Dose reduction, n (%) 19 (34.5) 0 14 (25.5) 26 (47.3)
C1 Dose interruption, n (%) 39 (70.9) 25 (45.5) 37 (67.3) 49 (89.1)
SD standard deviation
a Duration of exposure (weeks) = (date of last dose ? X - date of first dose ? 1)/7, where X is the number of days remaining to complete the
exposure time of the last dose
b Duration of exposure for combination treatment (weeks) = date of last dose ? X - date of first dose ? 1)/7, where X is the number of days
remaining to complete the exposure time of the last dose
c Relative dose intensity = dose intensity/planned dose intensity
Table 4 Best overall response (full analysis set; N = 55)
Everolimus ? trastuzumab ?
paclitaxel
Best overall response, n (%)
Complete 0
Partial 12 (21.8)
Stable disease 26 (47.3)
Progressive disease 8 (14.5)
Unknown 9 (16.4)
Overall response rate, n (%)a 12 (21.8)
95 % CI 11.8–35.0
Disease control rate, n (%)b 38 (69.1)
95 % CI 55.2–80.9
Clinical benefit rate, n (%)c 20 (36.4)
95 % CI 23.8–50.4
a Complete and partial responses
b Complete and partial responses plus stable disease
c Complete and partial responses plus stable disease C24 weeks
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Fig. 1 Kaplan–Meier analyses of progression-free survival in
patients with human epidermal growth factor receptor-2-positive
advanced breast cancer treated with everolimus (EVE), trastuzumab
(TRAS), and paclitaxel (T). CI confidence interval
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treatment due to stomatitis, and all 11 patients who expe-
rienced grade 3 stomatitis were brought to complete reso-
lution with dose interruption and/or dose reduction, along
with concomitant medication. Noninfectious pneumonitis
(including interstitial lung disease) was reported in 4
(7.3 %) patients. Grade 2 noninfectious pneumonitis events
were diagnosed in two patients and resolved completely
following dose interruption and dose reduction; grade 3
events were diagnosed in two patients and resulted in study
treatment discontinuation. Both patients who discontinued
were treated with steroid therapy and supplemental oxy-
gen; one event resolved 20 days after last study treatment,
and one was ongoing at the time of the last available report.
No grade 4 noninfectious pneumonitis events were reported
(Table 5).
Of the concomitant treatments allowed on study,
hematopoietic growth factors were used in 7.2 % of
patients who had documented cytopenia during/after cycle
1; baseline bisphosphonate treatment and analgesic medi-
cation (including opioids) were continued in 5.4 and
25.4 % of patients, respectively. Use of prophylactic anti-
emetic medications was continued from baseline in 5.4 %
of patients.
Discussion
The results from this phase 2 study provide additional clin-
ical support for the use of mTOR inhibitors to improve the
benefit of trastuzumab-based treatment strategies in women
with HER2-positive advanced breast cancer. In this study,
everolimus added to weekly trastuzumab and paclitaxel
yielded a 22 % ORR and 36 % CBR in heavily pretreated
patients with tumors exhibiting resistance to trastuzumab
(defined as disease progression within 3 months of their last
trastuzumab-containing regimen for advanced cancer, or
within 12 months after neo/adjuvant therapy). The median
PFS of 5.5 months was also encouraging given that the
majority of patients had progressed within 3 months of their
last regimen for advanced disease. In addition, the median
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Fig. 2 Kaplan–Meier analyses of overall survival in patients with
human epidermal growth factor receptor-2-positive advanced breast
cancer treated with everolimus (EVE), trastuzumab (TRAS), and
paclitaxel (T). CI confidence interval
Table 5 Adverse events irrespective of relation to study treatment
with C10 % incidence (any grade) or C5 % incidence (grade 3 or 4)
Adverse event (%)a Everolimus ? trastuzumab ? paclitaxel
(N = 55)
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic disorders
Neutropenia 0 7.3 25.5 3.6
Anemia 7.3 20.0 7.3 0
Leukopenia 0 3.6 16.4 1.8
Lymphopenia 0 0 18.2 1.8
Thrombocytopenia 1.8 9.1 5.5 1.8
Nonhematologic disorders
Stomatitis 23.6 32.7 20.0 0
Diarrhea 34.5 16.4 5.5 0
Asthenia 20.0 27.3 3.6 0
Rash 27.3 18.2 1.8 0
Headache 27.3 14.5 1.8 0
Pyrexia 21.8 16.4 0 1.8
Nausea 20.0 18.2 0 0
Cough 23.6 12.7 0 0
Peripheral neuropathy 27.3 5.5 3.6 0
Epistaxis 27.3 1.8 0 0
Vomiting 12.7 9.1 5.5 0
Constipation 21.8 1.8 0 0
Peripheral edema 18.2 5.5 0 0
Fatigue 9.1 7.3 5.5 0
Arthralgia 10.9 9.1 0 0
Nasopharyngitis 10.9 7.3 0 0
Erythema 10.9 7.3 0 0
Decreased appetite 10.9 7.3 0 0
Myalgia 14.5 3.6 0 0
Dyspnea 10.9 5.5 0 0
Muscle spasms 12.7 1.8 0 0
Dry skin 10.9 0 0 0
Insomnia 10.9 0 0 0
Hypophosphatemia 0 0 5.5 1.8
Pneumonia 0 0 5.5 0
The safety analyses excluded events that occurred[28 days after last
dose of study treatment
a A patient with multiple occurrences of an adverse event was
counted only once in the adverse event category. A patient with
multiple severity ratings for an adverse event was only included under
the maximum rating
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OS of 18 months was similar to the 23 months reported in a
phase 2 study of weekly trastuzumab and paclitaxel in
heavily pretreated patients (two or more prior lines of che-
motherapy) with trastuzumab-sensitive advanced HER2-
positive breast cancer (i.e., no prior exposure to trastuzumab)
[20].
Data from primary breast tumors suggest a causal rela-
tionship between PI3K/Akt/mTOR pathway activation and
overexpression of HER2, implicating the pathway in pro-
gression of HER2-positive breast cancer [21]. These find-
ings led to the examination of mTOR inhibition as a
strategy for improving sensitivity to trastuzumab-based
therapy [22]. This approach was found to be effective in
overcoming resistance to trastuzumab as well as in
restoring lapatinib sensitivity in several preclinical models
of HER2-positive breast cancer [15, 16, 23, 24]. Moreover,
in prospective data collected from patients with trast-
uzumab-refractory breast cancer, loss of HER2 overex-
pression was rare, whereas activation of the PI3K/Akt/
mTOR pathway through loss of PTEN or PIK3CA mutation
was frequently observed. Interestingly, a recent biomarker
analysis from the phase 3 CLEOPATRA study of pert-
uzumab in combination with trastuzumab and docetaxel
showed that PIK3CA mutations were associated with a
poor prognosis in patients with HER2-positive advanced
breast cancer in [25, 26]. However, this analysis did not
identify any predictive markers (other than HER2) for
response to anti-HER2 therapy; i.e., these biomarker
analyses did not provide any insight that would allow
refinement of the HER2-positive target population treated
with this drug regimen [26]. Analysis of potential bio-
markers (e.g., PTEN, HER2, and PI3K) that might predict
benefit from everolimus is beyond the scope of the current
phase 2 trial because of its small sample size. However,
these biomarkers are currently being analyzed in a large,
randomized, phase 3 trial of everolimus plus trastuzumab
in combination with paclitaxel (BOLERO-1), and this trial
may provide future insights into selecting the appropriate
patient population to treat with everolimus in combination
with available HER2-targeting agents.
Previously reported studies provide further support for
the activity of everolimus when combined with trast-
uzumab in heavily pretreated patients with HER2-positive
advanced breast cancer. In the 3-arm phase 1 dose-esca-
lation portion of this study, the ORR was 44 % in 27
evaluable patients from the whole study population and
was 31 % among 13 patients who received 10 mg/day
everolimus [19]. Likewise, another phase 1/2 study of ev-
erolimus in combination with weekly trastuzumab reported
a CBR of 34 % in a similar patient population with a high
burden of visceral disease that had received at least two
prior chemotherapy regimens for advanced breast cancer
[27].
In the current study, most of the patients had received
prior trastuzumab in the advanced setting and progressed
within 3 months. Only seven patients had disease recur-
rence/progression within 12 months of completing
(neo)adjuvant therapy. Therefore, the 5.5-month median
PFS should be interpreted in the context of the patient
population, which received a median of 3.5 prior lines of
therapy, and the majority had progressed rapidly on or after
their last trastuzumab-containing regimen for advanced
disease. Notably, among 52 patients with tumors consid-
ered resistant to trastuzumab-based therapy, 29 % had not
progressed at a median follow-up of 32.6 months. Taken
together, these data suggest that the combination of a
HER2-independent anticancer agent, such as everolimus,
with HER2-targeted treatment may delay disease progres-
sion in patients who develop trastuzumab-resistant disease.
With respect to taxane resistance, 73 % of eligible patients
had resistant tumors, and seven patients experienced dis-
ease progression during or within 4 months of their last
taxane-containing regimen. Thus, despite evidence of
resistance to both trastuzumab and taxane therapy, clinical
benefit was achieved with everolimus in combination with
trastuzumab and paclitaxel.
Safety findings from the phase 2 portion of the trial were
similar to observations during the phase 1 portion and
consistent with the reported safety profile of each of the
study drugs. No new safety signals were observed. As
expected, stomatitis was the most frequently reported
nonhematologic AE. By comparison, the most frequently
reported AEs in the everolimus plus exemestane arm in the
phase 3 BOLERO-2 study in hormone-receptor-positive
advanced breast cancer were stomatitis, fatigue, asthenia,
diarrhea, cough, pyrexia, and hyperglycemia. These are
consistent with the AEs previously reported with everoli-
mus monotherapy in other oncology indications [17, 28–
30]. Safety data from BOLERO-3, a phase 3 trial of ev-
erolimus and trastuzumab paired with vinorelbine instead
of paclitaxel for the treatment of patients with HER2-
positive advanced breast cancer, revealed a very similar
AE profile to that observed in the current phase 2 study. In
the initial report from BOLERO-3, the most frequently
reported nonhematologic AEs in the everolimus arm in
BOLERO-3 were stomatitis, fatigue, pyrexia, diarrhea,
nausea, and decreased appetite; commonly reported
hematologic AEs for the everolimus arm were neutropenia,
anemia, and leukopenia. The most common grade 3/4
nonhematologic AEs in the everolimus arm were stomati-
tis, fatigue, increased gamma-glutamyltransferase, and
asthenia; common hematologic grade 3/4 AEs were neu-
tropenia, leukopenia, anemia, and febrile neutropenia [31].
Overall, the nonhematologic AE profile of the combination
of trastuzumab and vinorelbine with everolimus in the
BOLERO-3 study was consistent with the known safety
444 Breast Cancer Res Treat (2013) 141:437–446
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profiles of the individual drugs, and no new unexpected
AEs were observed [31]. Final publication of the study
outcomes is awaited.
In the current study, AEs were generally manageable
with appropriate symptomatic treatment, dose interruptions
and reductions, and implementation of the management
guidelines per protocol, such as the introduction of hema-
topoietic growth factors in patients who experienced neu-
tropenia in cycle 1. AEs prompted at least one dose
reduction of everolimus in approximately one-third of
patients and at least one everolimus dose interruption in
62 % of patients. Similar proportions of patients required at
least one paclitaxel dose interruption or reduction because
of AEs. Notably, the most common AEs leading to dis-
continuation were lung-related AEs (six of ten patients who
discontinued study treatment because of AEs). However,
several patients had a history of underlying respiratory
disorders at study entry such as exertional dyspnea, pneu-
mothorax, and pulmonary embolism (n = 1 for each). Of
the remaining four patients who discontinued study treat-
ment because of AEs, two discontinued, in part, because of
febrile neutropenia and brain edema, which have not been
reported in breast cancer trials of everolimus in the absence
of a chemotherapy partner [32]. For all patients, diligent
screening as well as careful monitoring and appropriate
dose modifications are recommended to maximize clinical
benefit and minimize toxicity.
In conclusion, combining everolimus with trastuzumab
and paclitaxel provided substantial clinical benefit in this
heavily pretreated population of patients with HER2-posi-
tive advanced breast cancer who had progressed rapidly
during or after their last treatment regimen, the majority of
whom were resistant to trastuzumab and taxane treatment.
The promising results achieved with this regimen are cur-
rently being confirmed in the randomized, phase 3,
BOLERO–1 trial in the first-line setting.
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